Ratio Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
A developer of a proprietary platform for creating targeted radiopharmaceutical cancer therapies.
Oncology
Technology Platform
The Trillium platform integrates proprietary macropa chelators and linker chemistry to develop targeted alpha and beta particle radiopharmaceuticals.
Funding History
1Total raised:$50M
PIPE$50M
Opportunities
Capitalizing on the renaissance in radiopharmaceuticals to treat a wide array of cancers with a potentially best-in-class delivery platform.
Risk Factors
Complex manufacturing, regulatory hurdles for radioactive drugs, and competition from well-capitalized players with advanced clinical assets.
Competitive Landscape
Competes in the high-growth targeted radiopharmaceutical sector, where differentiation depends on isotope access, targeting precision, and linker-chelation technology.